作者
Kelly D. Farwell,Layla Shahmirzadi,Dima El-Khechen,Zöe Powis,Elizabeth Chao,Brigette Tippin Davis,Ruth Baxter,Weizhi Zeng,Cameron Mroske,Melissa Parra,Stephanie Gandomi,Ira Lu,Xiang Li,Hong Lu,Hsiao‐Mei Lu,David Salvador,David Ruble,Monica Lao,Soren Fischbach,Jennifer X. Wen,Shela Lee,Aaron Elliott,Charles L.M. Dunlop,Sha Tang
摘要
Diagnostic exome sequencing was immediately successful in diagnosing patients in whom traditional technologies were uninformative. Herein, we provide the results from the first 500 probands referred to a clinical laboratory for diagnostic exome sequencing.Family-based exome sequencing included whole-exome sequencing followed by family inheritance-based model filtering, comprehensive medical review, familial cosegregation analysis, and analysis of novel genes.A positive or likely positive result in a characterized gene was identified in 30% of patients (152/500). A novel gene finding was identified in 7.5% of patients (31/416). The highest diagnostic rates were observed among patients with ataxia, multiple congenital anomalies, and epilepsy (44, 36, and 35%, respectively). Twenty-three percent of positive findings were within genes characterized within the past 2 years. The diagnostic rate was significantly higher among families undergoing a trio (37%) as compared with a singleton (21%) whole-exome testing strategy.Overall, we present results from the largest clinical cohort of diagnostic exome sequencing cases to date. These data demonstrate the utility of family-based exome sequencing and analysis to obtain the highest reported detection rate in an unselected clinical cohort, illustrating the utility of diagnostic exome sequencing as a transformative technology for the molecular diagnosis of genetic disease.